Evidence map›Paper›PMID 30853512›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2019

Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

Arunasingam Abayasingam, Preston Leung, Auda Eltahla, Rowena A Bull, Fabio Luciani, Jason Grebely, Gregory J Dore, Tanya Applegate, Kimberly Page, Julie Bruneau and 11 more

Open access · greenAbstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Widespread hepatitis C virus transmission network among people who inject drugs in Kenya.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 4 countries.

Arunasingam AbayasingamSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Preston LeungThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Auda EltahlaSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Rowena A BullSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Fabio LucianiSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Jason GrebelyThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Gregory J DoreThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Tanya ApplegateThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Kimberly PageDivision of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico, Albuquerque, NM, USA.
Julie BruneauCRCHUM, Université de Montréal, Montreal, QC, Canada.
Andrea L CoxDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Arthur Y KimHarvard Medical School, Boston, MA, USA.
Janke SchinkelDepartment of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Center for Infection and Immunity Amsterdam, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands.
Naglaa H ShoukryCRCHUM, Université de Montréal, Montreal, QC, Canada.
Georg M LauerHarvard Medical School, Boston, MA, USA.
Lisa MaherThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Margaret HellardBurnet Institute, Melbourne, VIC, Australia; Monash University, Melbourne, Australia; Alfred Hospital, Melbourne, Australia; Doherty Institute and Melbourne School of Population and Global Health, University of Melbourne, Australia.
Maria PrinsDepartment of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Center for Infection and Immunity Amsterdam, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands; GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Andrew LloydThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Chaturaka RodrigoSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia. Electronic address: c.rodrigo@unsw.edu.au.
InC3 Study Group
UNSW Sydney · AUAmsterdam UMC Location University of Amsterdam · NLHarvard University · USUniversité de Montréal · CABurnet Institute · AUJohns Hopkins University · USUniversity of New Mexico · US

Funding

Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
CD4+ T Cells in Acute Versus Chronic HCV InfectionR01AI105035 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2013 to 2017
$2.3M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
Immune Control and Evadion during Acute HCV InfectionU01AI131314 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2016 to 2020
$1.4M
CIHR MOP-103138CIHR MOP-106468NIAID NIH HHS R01 AI105035NIAID NIH HHS U01 AI131314NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI088791NIDA NIH HHS R01 DA015999NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA031056
6 · The paper itself

Abstract

Transfer of hepatitis C virus (HCV) infection from a donor to a new recipient is associated with a bottleneck of genetic diversity in the transmitted viral variants. Existing data suggests that one, or very few, variants emerge from this bottleneck to establish the infection (transmitted founder [T/F] variants). In HCV, very few T/F variants have been characterized due to the challenges of obtaining early infection samples and of high throughput viral genome sequencing. This study used a large, acute HCV, deep-sequenced dataset from first viremia samples collected in nine prospective cohorts across four countries, to estimate the prevalence of single T/F viruses, and to identify host and virus-related factors associated with infections initiated by a single T/F variant. The short reads generated by Illumina sequencing were used to reconstruct viral haplotypes with two haplotype reconstruction algorithms. The haplotypes were examined for random mutations (Poisson distribution) and a star-like phylogeny to identify T/F viruses. The findings were cross-validated by haplotype reconstructions across three regions of the genome (Core-E2, NS3, NS5A) to minimize the possibility of spurious overestimation of single T/F variants. Of 190 acute infection samples examined, 54 were very early acute infections (HCV antibody negative, RNA positive), and single transmitted founders were identified in 14 (26%, 95% CI: 16-39%) after cross validation across multiple regions of the genome with two haplotype reconstruction algorithms. The presence of a single T/F virus was not associated with any host or virus-related factors, notably viral genotype or spontaneous clearance. In conclusion, approximately one in four new HCV infections originates from a single T/F virus. Resolution of genomic sequences of single T/F variants is the first step in exploring unique properties of these variants in the infection of host hepatocytes.

Indexed as

AdultDisease Transmission, InfectiousDrug UsersFemaleGenetic VariationGenome, ViralGenomicsHepacivirusHepatitis CHigh-Throughput Nucleotide SequencingHumansMalePhylogenyProspective StudiesYoung AdultHepatitis C virusInC3 studyNext generation sequencingPeople who inject drugsTransmitted-founder virus

Identifiers

PMID30853512
PMCPMC6487228
OpenAlexW2920917760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.